Catalyst

Slingshot members are tracking this event:

Phase 2/3 data of RG7916 in Spinal Muscular Atrophy (SMA) to be presented at AAN May 7, 2019 1pm.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
PTCT Community voting in process
RHHBY Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2/3, Rg7916, Spinal Muscular Atrophy